Cytogenetically normal acute myeloid leukemia [1]

New England Journal of Medicine

Volumn 359, Issue 6, 2008, Pages 651-653

  Büchner, Thomas ^a   Berdel, Wolfgang E ^a   Kienast, Joachim ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; NUCLEOPHOSMIN; NUCLEAR PROTEIN; ONCOPROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; DONOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; PRIORITY JOURNAL; GENE EXPRESSION; GENE MUTATION; MUTATION; NEUROBLASTOMA; ONCOGENE RAS; GENETICS; NOTE; STEM CELL TRANSPLANTATION; EPIDEMIOLOGY; HISTOCOMPATIBILITY TEST;

FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; ONCOGENE PROTEINS, VIRAL; STEM CELL TRANSPLANTATION; BIAS (EPIDEMIOLOGY); GENE EXPRESSION; HISTOCOMPATIBILITY TESTING;

EID: 49249095034     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc081230     Document Type: Letter

References (3)

1. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-18.
2. Cornelissen JJ, van Putten WLJ, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007;109:3658-66.
3. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1991;7:Suppl 3:9-12.